Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Myocardial Infarction and Ischaemic Stroke Following Exacerbations of Chronic Obstructive Pulmonary Disease.

Rothnie KJ, Connell O, Müllerová H, Smeeth L, Pearce N, Douglas I, Quint JK.

Ann Am Thorac Soc. 2018 May 3. doi: 10.1513/AnnalsATS.201710-815OC. [Epub ahead of print]

2.

Natural History of COPD Exacerbations in a General Practice Based COPD Population.

Rothnie KJ, Müllerová H, Smeeth L, Quint JK.

Am J Respir Crit Care Med. 2018 Feb 23. doi: 10.1164/rccm.201710-2029OC. [Epub ahead of print]

PMID:
29474094
3.

Validation of asthma recording in electronic health records: a systematic review.

Nissen F, Quint JK, Wilkinson S, Mullerova H, Smeeth L, Douglas IJ.

Clin Epidemiol. 2017 Dec 1;9:643-656. doi: 10.2147/CLEP.S143718. eCollection 2017. Review.

4.

Socioeconomic Status as a Determinant of Health Status Treatment Response in COPD Trials.

Jones PW, Gelhorn H, Wilson H, Benson VS, Karlsson N, Menjoge S, Müllerova H, Rennard SI, Tal-Singer R, Merrill D, Tabberer M.

Chronic Obstr Pulm Dis. 2017 Apr 1;4(2):150-158. doi: 10.15326/jcopdf.4.2.2017.0132.

5.

St George's Respiratory Questionnaire Score Predicts Outcomes in Patients with COPD: Analysis of Individual Patient Data in the COPD Biomarkers Qualification Consortium Database.

Müllerova H, Gelhorn H, Wilson H, Benson VS, Karlsson N, Menjoge S, Rennard SI, Tabberer M, Tal-Singer R, Merrill D, Jones PW.

Chronic Obstr Pulm Dis. 2017 Mar 28;4(2):141-149. doi: 10.15326/jcopdf.4.2.2017.0131.

6.

Baseline Severity as Predictor of Change in St George's Respiratory Questionnaire Scores in Trials of Long-acting Bronchodilators with COPD Patients.

Jones PW, Gelhorn H, Karlsson N, Menjoge S, Müllerova H, Rennard SI, Tal-Singer R, Wilson H, Merrill D, Tabberer M.

Chronic Obstr Pulm Dis. 2017 Mar 21;4(2):132-140. doi: 10.15326/jcopdf.4.2.2017.0129.

7.

Responder Analyses for Treatment Effects in COPD Using the St George's Respiratory Questionnaire.

Jones PW, Gelhorn H, Wilson H, Karlsson N, Menjoge S, Müllerova H, Rennard SI, Tal-Singer R, Merrill D, Tabberer M.

Chronic Obstr Pulm Dis. 2017 Mar 2;4(2):124-131. doi: 10.15326/jcopdf.4.2.2017.0130.

8.

The COPD Biomarkers Qualification Consortium Database: Baseline Characteristics of the St George's Respiratory Questionnaire Dataset.

Tabberer M, Benson VS, Gelhorn H, Wilson H, Karlsson N, Müllerova H, Menjoge S, Rennard SI, Tal-Singer R, Merrill D, Jones PW.

Chronic Obstr Pulm Dis. 2017 Mar 13;4(2):112-123. doi: 10.15326/jcopdf.4.2.2017.0128.

9.

Validation of asthma recording in the Clinical Practice Research Datalink (CPRD).

Nissen F, Morales DR, Mullerova H, Smeeth L, Douglas IJ, Quint JK.

BMJ Open. 2017 Aug 11;7(8):e017474. doi: 10.1136/bmjopen-2017-017474.

10.

Cardiovascular Disease Does Not Predict Exacerbation Rate or Mortality in Chronic Obstructive Pulmonary Disease.

Jones PW, Mullerova H, Agusti A, Decramer M, Adamek L, Raillard A, Zhu CQ, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):400-403. doi: 10.1164/rccm.201706-1066LE. No abstract available.

11.

Validity and interpretation of spirometric recordings to diagnose COPD in UK primary care.

Rothnie KJ, Chandan JS, Goss HG, Müllerová H, Quint JK.

Int J Chron Obstruct Pulmon Dis. 2017 Jun 7;12:1663-1668. doi: 10.2147/COPD.S133891. eCollection 2017.

12.

Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.

Albers FC, Müllerová H, Gunsoy NB, Shin JY, Nelsen LM, Bradford ES, Cockle SM, Suruki RY.

J Asthma. 2018 Feb;55(2):152-160. doi: 10.1080/02770903.2017.1322611. Epub 2017 Jun 16.

PMID:
28622052
13.

Validation of asthma recording in electronic health records: protocol for a systematic review.

Nissen F, Quint JK, Wilkinson S, Mullerova H, Smeeth L, Douglas IJ.

BMJ Open. 2017 May 29;7(5):e014694. doi: 10.1136/bmjopen-2016-014694. Review.

14.

The PLATINO study: description of the distribution, stability, and mortality according to the Global Initiative for Chronic Obstructive Lung Disease classification from 2007 to 2017.

Menezes AM, Wehrmeister FC, Perez-Padilla R, Viana KP, Soares C, Müllerova H, Valdivia G, Jardim JR, Montes de Oca M.

Int J Chron Obstruct Pulmon Dis. 2017 May 18;12:1491-1501. doi: 10.2147/COPD.S136023. eCollection 2017.

15.

Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.

Kardos P, Worsley S, Singh D, Román-Rodríguez M, Newby DE, Müllerová H.

Int J Chron Obstruct Pulmon Dis. 2016 Nov 25;11:2885-2895. eCollection 2016.

16.

Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records.

Rothnie KJ, Müllerová H, Thomas SL, Chandan JS, Smeeth L, Hurst JR, Davis K, Quint JK.

Clin Epidemiol. 2016 Nov 21;8:771-782. eCollection 2016.

17.

Bronchodilator reliever use and its association with the economic and humanistic burden of COPD: a propensity-matched study.

Punekar YS, Naya I, Small M, Holbrook T, Wood R, Mullerova H, Valle M.

J Med Econ. 2017 Jan;20(1):28-36. Epub 2016 Aug 26.

PMID:
27564685
18.

[French data from the Continuing to Confront COPD (C2C) survey].

Roche N, Ajjouri R, Compagnon A, Van Der Molen T, Mullerova H.

Rev Mal Respir. 2017 Mar;34(3):180-187. doi: 10.1016/j.rmr.2016.05.001. Epub 2016 Aug 8. French.

PMID:
27423810
19.

Prevalence and burden of dyspnoea among COPD patients in Japan.

Small M, Holbrook T, Wood R, Mullerova H, Naya I, Punekar YS.

Int J Clin Pract. 2016 Aug;70(8):676-81. doi: 10.1111/ijcp.12833. Epub 2016 Jul 11.

PMID:
27396989
20.

Health behaviors and their correlates among participants in the Continuing to Confront COPD International Patient Survey.

Müllerová H, Landis SH, Aisanov Z, Davis KJ, Ichinose M, Mannino DM, Maskell J, Menezes AM, van der Molen T, Oh YM, Tabberer M, Han MK.

Int J Chron Obstruct Pulmon Dis. 2016 Apr 27;11:881-90. doi: 10.2147/COPD.S102280. eCollection 2016. Erratum in: Int J Chron Obstruct Pulmon Dis. 2017 Mar 15;12 :859.

21.

Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records.

Rothnie KJ, Müllerová H, Hurst JR, Smeeth L, Davis K, Thomas SL, Quint JK.

PLoS One. 2016 Mar 9;11(3):e0151357. doi: 10.1371/journal.pone.0151357. eCollection 2016.

22.

Long-term Course of Depression Trajectories in Patients With COPD: A 3-Year Follow-up Analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Cohort.

Yohannes AM, Müllerová H, Hanania NA, Lavoie K, Tal-Singer R, Vestbo J, Rennard SI, Wouters EF.

Chest. 2016 Apr;149(4):916-26. doi: 10.1016/j.chest.2015.10.081. Epub 2016 Jan 5.

PMID:
26836938
23.

Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease.

Benson VS, Müllerová H, Vestbo J, Wedzicha JA, Patel A, Hurst JR; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators.

Respir Med. 2015 Sep;109(9):1147-54. doi: 10.1016/j.rmed.2015.06.009. Epub 2015 Jun 23.

24.

Clinical and prognostic heterogeneity of C and D GOLD groups.

Agustí A, Rennard S, Edwards LD, MacNee W, Wouters E, Miller B, Tal-Singer R, Mullerova H, Celli B; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators.

Eur Respir J. 2015 Jul;46(1):250-4. doi: 10.1183/09031936.00012215. No abstract available.

25.

One-year change in health status and subsequent outcomes in COPD.

Wilke S, Jones PW, Müllerova H, Vestbo J, Tal-Singer R, Franssen FM, Agusti A, Bakke P, Calverley PM, Coxson HO, Crim C, Edwards LD, Lomas DA, MacNee W, Rennard SI, Yates JC, Wouters EF, Spruit MA.

Thorax. 2015 May;70(5):420-5. doi: 10.1136/thoraxjnl-2014-205697. Epub 2015 Mar 17.

26.

Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study.

Müllerová H, Shukla A, Hawkins A, Quint J.

BMJ Open. 2014 Dec 18;4(12):e006171. doi: 10.1136/bmjopen-2014-006171.

27.

Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort.

Müllerova H, Maselli DJ, Locantore N, Vestbo J, Hurst JR, Wedzicha JA, Bakke P, Agusti A, Anzueto A.

Chest. 2015 Apr;147(4):999-1007. doi: 10.1378/chest.14-0655.

PMID:
25356881
28.

Characteristics of patients with COPD newly prescribed a long-acting bronchodilator: a retrospective cohort study.

Wurst KE, St Laurent S, Mullerova H, Davis KJ.

Int J Chron Obstruct Pulmon Dis. 2014 Sep 25;9:1021-31. doi: 10.2147/COPD.S58258. eCollection 2014.

29.

Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort.

Janssen DJ, Müllerova H, Agusti A, Yates JC, Tal-Singer R, Rennard SI, Vestbo J, Wouters EF; Eclipse Investigators.

Respir Med. 2014 Nov;108(11):1647-54. doi: 10.1016/j.rmed.2014.07.013. Epub 2014 Aug 7.

30.

Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD).

Quint JK, Müllerova H, DiSantostefano RL, Forbes H, Eaton S, Hurst JR, Davis K, Smeeth L.

BMJ Open. 2014 Jul 23;4(7):e005540. doi: 10.1136/bmjopen-2014-005540.

31.

Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care.

Müllerová H, Lu C, Li H, Tabberer M.

PLoS One. 2014 Jan 10;9(1):e85540. doi: 10.1371/journal.pone.0085540. eCollection 2014.

32.

COPD management costs according to the frequency of COPD exacerbations in UK primary care.

Punekar YS, Shukla A, Müllerova H.

Int J Chron Obstruct Pulmon Dis. 2014;9:65-73. doi: 10.2147/COPD.S54417. Epub 2014 Jan 9. Erratum in: Int J Chron Obstruct Pulmon Dis. 2014;9:247.

33.

Factors associated with change in exacerbation frequency in COPD.

Donaldson GC, Müllerova H, Locantore N, Hurst JR, Calverley PM, Vestbo J, Anzueto A, Wedzicha JA.

Respir Res. 2013 Jul 30;14:79. doi: 10.1186/1465-9921-14-79.

34.

Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort.

Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, Müllerova H, Lomas DA, Wouters E, Bakke P, Rennard S, Crim C, Miller BE, Coxson HO, Yates JC, Tal-Singer R, Vestbo J; ECLIPSE Investigators.

Eur Respir J. 2013 Sep;42(3):636-46. doi: 10.1183/09031936.00195212. Epub 2013 Jun 13.

35.

Cardiovascular comorbidity in COPD: systematic literature review.

Müllerova H, Agusti A, Erqou S, Mapel DW.

Chest. 2013 Oct;144(4):1163-1178. doi: 10.1378/chest.12-2847. Review.

PMID:
23722528
36.

[Changes in weight and diabetes compensation (HbA(1c)) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic - BIBY-I study (observations lasting 3 to 12 months)].

Perusicová J, Haladová I, Pit'hová P, Acsová D, Belobrádková J, Belzová A, Berková K, Dolezalová B, Dvoráková H, Hejnicová K, Hudcová M, Kallmünzerová D, Krejsová Z, Markofová G, Müllerová H, Owen K, Pelikánová M, Raclavská L, Racická E, Skarpová O, Váchová A, Veselá A, Vyoralos J, Broz J, Edelsberger T, Honka M, Hrdina T, Chmura P, Tosovský J.

Vnitr Lek. 2013 Mar;59(3):165-71. Czech.

PMID:
23713182
37.

[Changes in weight and diabetes compensation (HbA1c) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic -  BIBYII study (observations lasting 24 months)].

Perušičová J, Piťhová P, Haladová I, Diabetologů AP, Acsová D, Bělobrádková J, Belzová A, Berková K, Doležalová B, Dvořáková H, Hejnicová K, Hudcová M, Kallmünzerová D, Krejsová Z, Markofová G, Müllerová H, Owen K, Pelikánová M, Raclavská L, Račická E, Skarpová O, Váchová A, Veselá A, Vyoralová J, Brož J, Edelsberger T, Honka M, Hrdina T, Chmura P, Tosovsky J.

Vnitr Lek. 2013 Apr;59(4):249-55. Czech.

PMID:
23711049
38.

Fatigue in COPD and the impact of respiratory symptoms and heart disease--a population-based study.

Stridsman C, Müllerova H, Skär L, Lindberg A.

COPD. 2013 Apr;10(2):125-32. doi: 10.3109/15412555.2012.728642.

PMID:
23547627
39.

Association of heart diseases with COPD and restrictive lung function--results from a population survey.

Eriksson B, Lindberg A, Müllerova H, Rönmark E, Lundbäck B.

Respir Med. 2013 Jan;107(1):98-106. doi: 10.1016/j.rmed.2012.09.011. Epub 2012 Nov 3.

40.

Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD.

Pinto-Plata V, Casanova C, Müllerova H, de Torres JP, Corado H, Varo N, Cordoba E, Zeineldine S, Paz H, Baz R, Divo M, Cortopassi F, Celli BR.

Respir Res. 2012 Aug 20;13:71. doi: 10.1186/1465-9921-13-71.

41.

The natural history of community-acquired pneumonia in COPD patients: a population database analysis.

Müllerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ, Wedzicha JA.

Respir Med. 2012 Aug;106(8):1124-33. doi: 10.1016/j.rmed.2012.04.008. Epub 2012 May 22.

42.

Fibrinogen, COPD and mortality in a nationally representative U.S. cohort.

Mannino DM, Valvi D, Mullerova H, Tal-Singer R.

COPD. 2012 Aug;9(4):359-66. doi: 10.3109/15412555.2012.668249. Epub 2012 Apr 11.

PMID:
22489912
43.

Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts.

Valvi D, Mannino DM, Müllerova H, Tal-Singer R.

Int J Chron Obstruct Pulmon Dis. 2012;7:173-82. doi: 10.2147/COPD.S29892. Epub 2012 Mar 7.

44.

Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort.

Hanania NA, Müllerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, Rennard SI, Sharafkhaneh A; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators.

Am J Respir Crit Care Med. 2011 Mar 1;183(5):604-11. doi: 10.1164/rccm.201003-0472OC. Epub 2010 Oct 1.

PMID:
20889909
45.

Susceptibility to exacerbation in chronic obstructive pulmonary disease.

Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators.

N Engl J Med. 2010 Sep 16;363(12):1128-38. doi: 10.1056/NEJMoa0909883.

46.

C-reactive protein levels and survival in patients with moderate to very severe COPD.

de Torres JP, Pinto-Plata V, Casanova C, Mullerova H, Córdoba-Lanús E, de Fuentes MM, Aguirre-Jaime A, Celli BR.

Chest. 2008 Jun;133(6):1336-1343. doi: 10.1378/chest.07-2433. Epub 2008 Mar 13.

PMID:
18339787
47.

[Chronic obstructive pulmonary disease (COPD) burden in Japan--confronting COPD Japan survey].

Ichinose M, Aizawa H, Ishizaka A, Nagai A, Fukuchi Y, Mullerova H, Crane M.

Nihon Kokyuki Gakkai Zasshi. 2007 Dec;45(12):927-35. Japanese.

PMID:
18186237
48.

Profiling serum biomarkers in patients with COPD: associations with clinical parameters.

Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, De Souza MM, Vessey R, Celli B.

Thorax. 2007 Jul;62(7):595-601. Epub 2007 Mar 13.

49.

Inflammatory changes, recovery and recurrence at COPD exacerbation.

Perera WR, Hurst JR, Wilkinson TM, Sapsford RJ, Müllerova H, Donaldson GC, Wedzicha JA.

Eur Respir J. 2007 Mar;29(3):527-34. Epub 2006 Nov 15.

50.

Supplemental Content

Loading ...
Support Center